The association of adequate empirical treatment and time to recovery from bacteraemic urinary tract infections: a retrospective cohort study

Our objective was to evaluate whether patients with bacteraemic urinary tract infection (UTI) who receive inadequate empirical therapy have worse outcomes than those with adequate therapy. This was a retrospective cohort study of patients with bacteraemic UTI. The exposure variable was adequate vers...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical microbiology and infection 2019-10, Vol.25 (10), p.1253-1258
Hauptverfasser: Wiggers, J.B., Sehgal, P., Pinto, R., MacFadden, D., Daneman, N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Our objective was to evaluate whether patients with bacteraemic urinary tract infection (UTI) who receive inadequate empirical therapy have worse outcomes than those with adequate therapy. This was a retrospective cohort study of patients with bacteraemic UTI. The exposure variable was adequate versus inadequate empirical antibiotic therapy (AEAT versus IEAT) within 24 h of culture collection. Primary endpoint was time to cure. The primary analysis used propensity score models with inverse probability of treatment weights. A secondary Cox proportional hazards modelling approach was used to test the robustness of this finding, and to evaluate other patient and pathogen predictors of time to cure. Of 469 patients with bacteraemic UTI, 368 (78.5%) received AEAT. There was no significant difference in mortality between those receiving AEAT and those receiving IEAT (adjusted OR 0.86, 95%CI 0.47–1.58). Receipt of AEAT had no association with time to cure (HR 0.93, 95%CI 0.73–1.19, p 0.55) or time to normalization of individual clinical variables. Cox proportional hazards modelling revealed that longer time to cure was associated with liver disease (HR 0.25, 95%CI 0.08–0.76, p 0.015), prior stroke (HR 0.73, 95%CI 0.54–0.99, p 0.044), empirical receipt of piperacillin–tazobactam (HR 0.77, 95%CI 0.59–0.99, p 0.044), qSOFA score >1 (HR 0.68, 95%CI 0.55–0.84, p 
ISSN:1198-743X
1469-0691
DOI:10.1016/j.cmi.2019.02.027